Financial Highlights - ChromaDex's total net sales reached $83.5 million in 2023, with Tru Niagen® sales contributing $69.5 million[14] - Tru Niagen® sales experienced a 52% Compound Annual Growth Rate (CAGR)[11] - E-commerce net sales reached $51.2 million in 2023, demonstrating an 85% CAGR[16] - Gross margin increased from 49.4% to 60.8% following a strategic shift towards Tru Niagen®[17] - ChromaDex reported a positive Adjusted EBITDA of $1.9 million in 2023[11, 12] Market and Product - ChromaDex identifies as the global authority on NAD+ with a Total Addressable Market (TAM) exceeding $500 billion across human and pet nutrition, cosmetics, and pharmaceuticals[11] - Tru Niagen® is identified as a proprietary NAD+ boosting supplement[11] - Approximately 60% of ChromaDex's business is attributed to e-commerce[15] - North America accounts for 75% of Tru Niagen® net sales, followed by APAC with 22%[56] Research and Development - ChromaDex has invested in over $100 million of third-party research supporting the benefits of its proprietary ingredient[11] - ChromaDex holds a strong intellectual property portfolio, including over 80 patents for Niagen® and other NAD+ precursors[11]

Company Overview - ChromaDex is a global authority on NAD+ with a strong intellectual property portfolio for Niagen® and other NAD precursors[8] - The company has strategic partnerships with blue chip companies and a strong financial position, with $4 million LTM Adjusted EBITDA and $28 million in cash as of June 30, 2024[8] - ChromaDex's LTM revenue ended June 2024 was $856 million, with a net loss of $14 million and non-GAAP Adjusted EBITDA of $4 million[25] Consumer Health (Tru Niagen®) - Tru Niagen® has proven to be a proprietary NAD+ boosting supplement with LTM sales of over $80 million[8] - E-commerce represents approximately 60% of the Tru Niagen® business[34] - Annual e-commerce net sales have grown at a CAGR of 85% from 2017 to 2023[35], reaching $512 million in 2023[35] - Gross margin increased from 494% to 608% since the strategic pivot to focus on the consumer product, Tru Niagen®[36] IV & Injectables (Niagen®+) - The company estimates the incumbent NAD+ IV retail market in North America is worth at least $100 million[49] - Niagen®+ IV offers competitive advantages over NAD+ IV, including 75% faster infusion time and minimal side effects[50] Pharmaceutical - ChromaDex is pioneering the development of Parkinson's Disease treatment, with a Phase III study underway involving 400 participants supplemented with NR for 12 months at a 1000mg daily dose, with results expected in 2025[59, 60] Financial Outlook - The company projects net sales growth between 10%-15% year-over-year for 2024[69]

Summary of Niagen Bioscience Conference Call Company Overview - Niagen Bioscience is focused on the development and commercialization of nicotinamide riboside (Niagen), a molecule that elevates NAD levels in cells, which is crucial for energy metabolism and cellular repair [5][7][8] - The company has over 90 patents protecting its core molecule and has built a strong scientific foundation with extensive research [8][14] Core Points and Arguments - **Scientific Research and Clinical Studies**: Niagen has conducted 40 peer-reviewed clinical studies demonstrating the safety and efficacy of its product, particularly in age-related conditions [7][18][24] - **Unique Positioning**: Unlike many dietary supplement companies, Niagen is rooted in scientific research and intellectual property, which differentiates it from competitors that primarily engage in marketing [11][14][17] - **Regulatory Challenges**: The company faces strict regulations that prevent it from making health claims typically associated with drugs, which influences its marketing strategy [23][24] - **Market Strategy**: Niagen relies on word-of-mouth and expert endorsements rather than direct consumer claims to build trust and credibility [24][25] Recent Developments - **Product Launches**: The company launched the Niagen Plus line, which includes IV products and at-home injectables, generating significant media attention and interest from celebrities and influencers [34][35][40] - **Clinical Trials**: A phase three clinical study on Parkinson's disease with 400 participants is nearing completion, which could significantly impact the company's valuation and credibility in the biotech space [18][54] - **Financial Health**: Niagen is cash flow positive, has no debt, and does not require additional capital for its operations, which is atypical for biotech companies [52][54] Potential Risks and Concerns - **Market Competition**: The rise of fraudulent companies claiming to offer NAD products poses a risk to the overall market perception and could impact Niagen's reputation [27][29] - **Consumer Education**: There is a need to educate consumers about the differences between Niagen and other NAD products, particularly regarding bioavailability and efficacy [27][37] Future Outlook - **Injectable Products**: The company plans to introduce a self-injection product within the next year, tapping into the growing trend of self-administered health solutions [49][50] - **Pharmaceutical Opportunities**: Niagen is exploring drug indications beyond dietary supplements, which could enhance its market position and attract sophisticated investors [54] Conclusion - Niagen Bioscience is well-positioned in the NAD market with a strong scientific foundation, innovative products, and a clear strategy to navigate regulatory challenges while maintaining financial stability. The company's focus on research and quality sets it apart from competitors, and its future product developments could significantly expand its market reach and impact.

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $30,500,000, representing a 38% year-over-year increase [8][18] - Net income for the quarter was $5,100,000, compared to a net loss of $500,000 in Q1 2024 [21] - Cash generated from operations was $7,900,000, a significant increase from $300,000 in the same period last year [22] - The company ended the quarter with $55,600,000 in cash and no debt, maintaining strong liquidity [21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [9][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8,000,000 [9][18] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and cost savings [18] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company aims to expand its presence in clinics, targeting 1,000 clinics by the end of 2025, with a potential addressable market of 2,000 to 3,000 clinics [42] Company Strategy and Development Direction - The company is focused on reinforcing Niagen as the leading NAD-boosting solution, aligning its brand with its mission of promoting healthy aging [15][16] - The pharmaceutical application of nicotinamide riboside (NR) is a key strategic initiative, with ongoing studies and FDA dialogues [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook to 20% to 25% [22][23] - The company is committed to operational discipline and efficiency, with a focus on long-term profitability [26] Other Important Information - The company announced a new composition of matter patent granted in March, broadening its patent portfolio [11] - Management highlighted the importance of maintaining integrity and scientific rigor in the NAD supplement market [13][14] Q&A Session Summary Question: What are the emerging tailwinds for NIAGEN IV product adoption? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and expectations for increased sales [28][32] Question: Are there new promotional strategies for e-commerce? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers [35][37] Question: What is the potential market for NIAGEN plus? - Management aims to onboard 1,000 clinics by year-end, with a larger addressable market identified [42] Question: What is the status of the injectable NIAGEN plus? - Management confirmed that an at-home version is in development, expected to be available by Q4 2025 [72][73] Question: What is the status of the FDA discussions regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received [90][91]

Financial Data and Key Metrics Changes - In Q1 2025, Niagen Bioscience reported revenues of $30.5 million, a 38% year-over-year increase, and net income of $5.1 million, compared to a net loss of $0.5 million in Q1 2024 [7][22] - The company generated $7.9 million in cash from operations, a significant increase from $0.3 million in the same period last year [22][23] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and supply chain cost savings [19][22] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [8][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8 million [8][18] - The Niagen plus product line, which includes intravenous and injection forms, is a key focus area, with availability in nearly 600 clinics nationwide [8][10] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company is actively monitoring the competitive landscape, noting that many NAD supplements on the market do not meet label claims [14] Company Strategy and Development Direction - Niagen Bioscience aims to position itself as the leader in NAD-boosting solutions, emphasizing scientific rigor, transparency, and integrity [16] - The company is focused on expanding its pharmaceutical applications, particularly in ongoing clinical studies for Parkinson's disease and ataxia telangiectasia [10][11] - The recent rebranding from ChromaDex to Niagen Bioscience aligns with its mission to promote healthy aging [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook from approximately 18% to a range of 20% to 25% [24][25] - The company is committed to operational discipline and efficiency, with expectations of steady gross margins and sustained profitability [25][26] Other Important Information - Niagen Bioscience has established a primarily U.S.-based supply chain, which remains unaffected by recent tariffs [20] - The company has received a new composition of matter patent, broadening its intellectual property portfolio [11] Q&A Session Summary Question: What are the emerging tailwinds for the adoption of the NIAGEN IV product lineup? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and positive feedback on its benefits compared to traditional NAD IV [28][29] Question: What new promotional strategies are expected for the e-commerce business? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers, but no aggressive campaigns are planned [33][34][36] Question: How many clinics are expected to adopt NIAGEN plus by the end of the year? - Management aims to have NIAGEN plus in 1,000 clinics by year-end, with a potential addressable market of 2,000 to 3,000 clinics [41][42] Question: What is the status of the injectable NIAGEN plus product? - The injectable product is currently offered in many clinics, with plans for an at-home version expected by Q4 2025 [72][73] Question: What is the status of discussions with the FDA regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received, indicating progress [88][89]

Financial Performance - Q1 2025 - Total company net sales reached $30.5 million, a 38% increase year-over-year (YoY)[10] - Tru Niagen® net sales were $21.5 million, up 24% YoY[10] - Niagen® ingredient sales increased significantly to $8.0 million, a 95% YoY increase[10] - Gross margin improved to 63.4%, a 270 basis points increase YoY[10] - Net income was $5.1 million, or $0.07 earnings per share, an increase of $5.6 million and $0.08 YoY[10] - Adjusted EBITDA was $4.9 million, up $4.2 million YoY[10] - The company ended the quarter with $55.6 million in cash and no debt, with cash provided from operations at $7.9 million year-to-date[10] Sales Mix - Q1 2025 - E-commerce accounted for 58% of net sales in Q1 2025, compared to 55% in Q1 2024[26] - Watson's & Other B2B represented 20% of net sales in Q1 2025, up from 16% in Q1 2024[26] - Food-grade Niagen® contributed 19% of net sales in Q1 2025, down from 23% in Q1 2024[26] - Tru Niagen® net sales accounted for 71% of total net sales in Q1 2025, compared to 78% in Q1 2024[27] - Niagen®-related net sales remained at 97% of total net sales in both Q1 2025 and Q1 2024[27] Financial Outlook - 2025 - The company adjusted its full-year 2025 net sales growth outlook to between 20%-25%, previously approximately 18%[10] - Adjusted general and administrative expenses outlook was revised upwards by $7.0 to $8.0 million, previously $5.0 to $6.0 million[10]

Financial Performance - Total net sales reached $30.5 million, an increase of $8.3 million or 38% year-over-year, with a gross margin of 63.4%[1][4] - Net income was $5.1 million, or $0.07 per share, compared to a net loss of $0.5 million or $(0.01) per share in the prior year quarter[7][20] - Adjusted EBITDA improved to $4.9 million, up from $0.7 million in the first quarter of 2024[7][20] - Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% year-over-year[4][5] - Cash provided by operations was $7.9 million, compared to $0.3 million in the prior year[8][20] - Net income for Q1 2025 was reported at $5,063,000, compared to a net income of $7,179,000 in Q4 2024, indicating a decrease of 29.5%[27] - Adjusted EBITDA for Q1 2025 was $4,894,000, up from $3,371,000 in Q4 2024, reflecting a growth of 45.0%[27] Future Outlook - The company expects full year 2025 net sales growth between 20% and 25%, an increase from the previous estimate of approximately 18%[4][9] Expenses and Liabilities - Selling and marketing expenses as a percentage of net sales improved by 380 basis points to 26.6%[4][10] - General and administrative expenses are expected to increase by approximately $7.0 to $8.0 million due to revised share-based compensation estimates[4][9] - Total current liabilities increased to $20,837,000 as of March 31, 2025, from $17,948,000 on December 31, 2024, an increase of 10.5%[23] Assets and Equity - Total assets increased to $81,337,000 as of March 31, 2025, up from $68,278,000 on December 31, 2024, representing a growth of 19.1%[23] - Cash and cash equivalents at the end of Q1 2025 reached $55,616,000, compared to $27,565,000 at the end of Q1 2024, marking a 101.5% increase[25] - Total stockholders' equity increased to $55,345,000 as of March 31, 2025, up from $46,094,000 on December 31, 2024, a growth of 20.0%[23] Cash Flow - Net cash provided by operating activities for Q1 2025 was $7,883,000, a significant increase from $295,000 in Q1 2024[25] - The company reported a net increase in cash and cash equivalents of $10,956,000 for Q1 2025, compared to an increase of $240,000 in Q1 2024[25] Inventory and Receivables - Trade receivables decreased to $7,052,000 as of March 31, 2025, down from $7,768,000 on December 31, 2024, a decline of 9.2%[23] - Inventories rose to $11,185,000 as of March 31, 2025, compared to $9,192,000 on December 31, 2024, an increase of 21.7%[23] Corporate Changes - The company announced a corporate name change to Niagen Bioscience, Inc. and began trading under the new Nasdaq ticker "NAGE" effective March 19, 2025[4] - The company expanded its NAD+ precursor patent portfolio with a newly granted patent covering NR salt forms[4]

Financial Performance - For the three months ended March 31, 2025, total net sales increased by approximately $8.3 million, reaching $30.5 million, a 38% increase compared to $22.2 million in the same period of 2024[107]. - Net income for the three months ended March 31, 2025, was $5.1 million, compared to a net loss of $0.5 million in the same period of 2024[107]. - Basic income per share increased to $0.07 for the three months ended March 31, 2025, compared to a loss of $0.01 per share in the prior year[107]. - Total gross profit for the three months ended March 31, 2025, was $19,331,000, a 44% increase from $13,456,000 in the same period of 2024[110]. Segment Performance - Consumer Products segment net sales grew by 24% to $21.5 million, driven by a $4.0 million increase in e-commerce sales reflecting strong consumer demand[108]. - Ingredients segment net sales doubled to $8.2 million, primarily due to $2.9 million in sales to food-grade Niagen® partners and $1.0 million from pharmaceutical-grade Niagen® launched in 2024[108]. - The consumer products segment gross profit increased by 26% to $14,094,000, while the ingredients segment saw a 125% increase to $5,068,000[110]. Operational Efficiency - Total cost of sales improved to $11.2 million, representing 37% of net sales, down from 39% in the same period of 2024, indicating enhanced operational efficiency[109]. - Sales and marketing expenses rose by $1.4 million, or 20%, to $8,117,000, but improved as a percentage of net sales by 380 basis points to approximately 27%[112]. - Research and development expenses decreased by 40% to $1,258,000, down from $2,095,000 in the prior year, reflecting normalized spending after the launch of the Niagen Plus product line[113]. - General and administrative expenses were relatively flat at $5,184,000, a 3% decrease from $5,352,000, primarily due to a reduction in credit loss expense[114]. Cash Flow and Financial Position - The company had cash and cash equivalents of approximately $55.6 million as of March 31, 2025, with $55.5 million being unrestricted[104]. - Net cash provided by operating activities was approximately $7.9 million for the three months ended March 31, 2025, compared to $0.3 million in the same period of 2024[125]. - Cash provided by financing activities was $3.1 million for the three months ended March 31, 2025, compared to a use of cash of $14,000 in the same period of 2024[128]. - The company anticipates that current cash and cash equivalents will be sufficient to meet financial obligations for at least the next twelve months[124]. Inventory and Lease Obligations - The company is obligated to purchase approximately $16.4 million of inventory under a rolling forecast with W.R. Grace between April 1, 2025, and September 30, 2025[101]. - The company amended its lease in Longmont, Colorado, resulting in an estimated increase in lease liability and right-of-use asset of approximately $1.1 million[100]. Research and Development - The company has over 300 research partnerships through its ChromaDex External Research Program (CERP™), enhancing its position in NAD+ research and development[98].

Company Overview - ChromaDex Corporation (NASDAQ: CDXC) is a bioscience company focused on cellular health and longevity, aiming to enhance the efficiency and lifespan of cells [1] Mission and Principles - Grassroots Trading emphasizes providing objective, unbiased, and balanced research, supported by solid data without emotional influences [1] - The focus is primarily on small- to mid-cap companies, offering compelling investment insights on often overlooked opportunities [1] - The scope also includes identifying potential opportunities in large- and mega-cap companies, thereby covering a broad spectrum of the dynamic equity markets [1]

ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward- looking statements reflect the current view about future events. Statements that are not historical in na ...